Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment

Meir, Priel; Taylor, Leslie K.; Soares, Jair C.; Meyer, Thomas D.

doi:10.1016/j.jad.2022.12.050

Cited by 9 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…See Table 2 for participantrequested supports before, during, and after psilocybin therapy. While previous studies have described therapist openness to referral and attitudes towards psychedelic therapies, our study newly uncovers stakeholder beliefs around partnership with the team implementing psilocybin therapy (Davis et al, 2022;Meir et al, 2023;Meyer et al, 2022). Even without a formal role in the intervention, community providers frame the treatment for patients, provide T A B L E 2 Additional education and collaboration requested by participants.…”

Section: Resultsmentioning

confidence: 89%

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy

Downey

Boyd

Chaphekar

et al. 2023

Intl J Eating Disorders

View full text Add to dashboard Cite

ObjectiveThis study invited providers who care for patients with eating disorders to inform engagement, communication, and collaboration with psilocybin‐assisted psychotherapy interventions.MethodMedical and mental health providers who treat patients with eating disorders were recruited via professional referral networks and participant driven sampling from across California to participate in one of five focus groups. Discussion topics included prior knowledge of psychedelic therapy, interest/concerns related to psilocybin therapy, and opportunities for collaboration. Study team members completed iterative rounds of coding with a grounded theory approach.ResultsA total of 32 participants reported a range of familiarity with psychedelics. Some raised concerns about the risks of administering psilocybin to malnourished patients and to those with psychological comorbidities. Despite these concerns, participants were hopeful to see psilocybin therapy as a treatment for patients with eating disorders. In anticipating challenges, providers had concerns about equity in access to care among publicly insured and non‐English speaking patients. They requested opportunities for continuing education about psilocybin therapy.DiscussionOur findings demonstrate provider interest in psilocybin therapy for the treatment of patients with eating disorders. As psilocybin therapy interventions are developed, providers caring for patients with eating disorders value collaboration to improve longitudinal patient outcomes.Public SignificanceThis study invited healthcare providers of patients with eating disorders to discuss their thoughts around the use of psilocybin‐assisted psychotherapy in this population. Findings will help inform emerging psilocybin therapy clinical trials with the goal of successful translation and adoption in real world clinical settings.

show abstract

Section: Resultsmentioning

confidence: 89%

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy

Downey

Boyd

Chaphekar

et al. 2023

Intl J Eating Disorders

View full text Add to dashboard Cite

show abstract

“…Openness and knowledge of PAT among psychotherapists are particularly important for the popularisation of psychedelic therapy. Meir et al (2023) assessed the openness of psychotherapists to engage their patients in psilocybin-assisted therapy. Although 77.4% of therapists agreed they would inform eligible patients about PAT, most would still recommend traditional psychotherapy.…”

Section: The Role Of Informed Public Discoursementioning

confidence: 99%

Need for a broader discussion on psychedelic therapy

Holas

2023

Psychiatr Psychol Klin

View full text Add to dashboard Cite

“…Þekking og viðhorf fagfólks á hugvíkkandi efnum hefur verið athuguð í nokkrum erlendum rannsóknum. [9][10][11][12][13] Í ljósi aukinnar umraeðu og nokkurrar útbreiðslu notkunar hugvíkkandi efna úti í samfélaginu, töldum við mikilvaegt að safna upplýsingum um viðhorf fagaðila til efnanna, ásamt því að skoða hversu vel fagaðilar telja sig þekkja slík efni, virkni þeirra og hugsanlegan meðferðarárangur. Einnig er áhugavert að kanna hugmyndir heilbrigðisstarfsfólks um veitingu slíkrar meðferðar, það er, hvar og hvernig aetti að veita hana, hverjir aettu að sinna því og hvar þjálfun fagfólks vaeri best fyrir komið, ef til þess kaemi að meðferð með efnunum yrði veitt.…”

Section: Hugvíkkandi Efni Og Meðhöndlun Geðraskana á íSlandiunclassified

“…Erlendar rannsóknir sýna að afstaða fagaðila er almennt neikvaeð til notkunar hugvíkkandi efna í meðferðartilgangi, meðal annars vegna skorts á þekkingu og fraeðslu, en áhugi er á áframhaldandi rannsóknum. [9][10][11][12][13] Niðurstöður þessarar rannsóknar eru því í samraemi við þetta. Vandaðar árangursrannsóknir eru enn fáar á þessu sviði.…”

Section: Umraeðaunclassified

Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland

Ólafsson,

Kvaran,

Ketilsdóttir

et al. 2023

LBL

View full text Add to dashboard Cite

INTRODUCTION: Interest in the use of psychedelics has increased following reports of their possible therapeutic potential. However, little is known about the knowledge of and attitudes towards the substances among health care professional who provide treatment for mental disorders in Iceland. An online survey was therefore conducted among members of the Icelandic associations of psychiatrists, general practitioners and psychologists. METHODS: Respondents were 256 in total, including 177 psychologists, 38 psychiatrists and 41 general practitioners that provided information on their background, type of work, knowledge of and attitude towards different types of psychedelic substances and their views on optimal service delivery if psychedelics were approved by licencing authorities and used for treatment. RESULTS: Around half of psychiatrists reported having received questions about treatment with psychedelics in their clinical work, compared to only 14,6% of general practitioners and 17,5% of psychologists. The majority of respondents had little, or no knowledge of the substances targeted in the survey. A majority also expressed negative attitudes towards treatment with psilocybin mushrooms, but was positive towards ongoing scientific research and felt that such a treatment should be prescribed and provided by psychiatrists. Moreover, the majority view was that psilocybin treatment should be provided in specialised clinics or psychiatric units in a hospital setting. Scientific articles on the topic, discussions with colleagues and information in the media were identified as having had most influence on respondents´ attitudes towards psychedelics. Most respondents were interested in further education on psychedelics. CONCLUSIONS: Respondents among these three professions felt that the time has not yet come to use psychedelics in the treatment of mental disorders in Iceland but thought more education on psychedelics, their potential efficacy and adverse health effects is important given the increased interest in psychedelics.

show abstract

Psychotherapists' openness to engage their patients in Psilocybin-Assisted Therapy for mental health treatment

Cited by 9 publications

References 39 publications

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy

“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy

Need for a broader discussion on psychedelic therapy

Psychedelics and treatment of mental disorders: A survey of attitudes and knowledge among psychiatrists, general practitioners and psychologists in Iceland

Contact Info

Product

Resources

About